Cytyc Together with Hologic: There's a Certain Logic

What do you get when you cross a women's health company that sells screening and diagnostic imaging technologies to hospitals and radiologists, with a women's health company that sells diagnostics and therapeutic devices to Ob-Gyns? A single company capable of selling goods and services across the entire continuum of care, according to Rob Cascella, president & COO of Hologic, who thus revealed the reasoning behind the $6.5 billion proposed merger of Hologic with Cytyc.

What do you get when you cross a women’s health company that sells screening and diagnostic imaging technologies to hospitals and radiologists, with a women’s health company that sells diagnostics and therapeutic devices to Ob-Gyns? A single company capable of selling goods and services across the entire continuum of care, according to Rob Cascella, president & COO of Hologic Inc., who thus revealed the reasoning behind the $6.5 billion proposed merger of Hologic with Cytyc Corp.[See Deal]

The deal—which still awaits shareholder approval—would create a leading women’s health care company with $1.7 billion in annual sales derived from a healthy mix of capital equipment and disposable-based businesses

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.